Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Left To Its Own Devices? Olympus Recall Pushed Into Spotlight

This article was originally published in The Gray Sheet

Executive Summary

Olympus America is conducting a telephone campaign to aid the Melville, New York company's recall of 15 models of its bronchoscopes that contain a design flaw

You may also be interested in...



Bronchoscope safety

Outbreak of P. aeruginosa infections in 2001-2002 apparently was caused by loose bronchoscope biopsy-port caps, according to a study by David Kirschke, MD, CDC, et al., published in the Jan. 16 New England Journal of Medicine. A federal mandate that recall notices be sent to all physicians who may use the device could have shortened the outbreak, Kirschke notes, concluding that "instrument safety and surveillance methods for bronchoscopy must be improved." In an editorial, CDRH Director David Feigal counters that FDA's MeDSuN surveillance program helps health care facilities minimize the risk of device-related injuries, offering that the system's first 224 reports, 205 of which were voluntary, included two deaths and 17 serious injuries. Both FDA and bronchoscope manufacturer Olympus America came under fire for late reporting of the original infections (1"The Gray Sheet" March 11, 2002, p. 24)...

Bronchoscope safety

Outbreak of P. aeruginosa infections in 2001-2002 apparently was caused by loose bronchoscope biopsy-port caps, according to a study by David Kirschke, MD, CDC, et al., published in the Jan. 16 New England Journal of Medicine. A federal mandate that recall notices be sent to all physicians who may use the device could have shortened the outbreak, Kirschke notes, concluding that "instrument safety and surveillance methods for bronchoscopy must be improved." In an editorial, CDRH Director David Feigal counters that FDA's MeDSuN surveillance program helps health care facilities minimize the risk of device-related injuries, offering that the system's first 224 reports, 205 of which were voluntary, included two deaths and 17 serious injuries. Both FDA and bronchoscope manufacturer Olympus America came under fire for late reporting of the original infections (1"The Gray Sheet" March 11, 2002, p. 24)...

Bronchoscope Safety Feature Rides Consumer Awareness Of Olympus Recall

Vision-Sciences, Inc. will emphasize the safety aspects of its EndoSheath bronchoscope system at the World Congress of Bronchology meeting in Boston June 17-18 in preparation for a full-scale launch in July

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel